Sarcoma  >>  letetresgene autoleucel (GSK3377794)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
letetresgene autoleucel (GSK3377794) / Adaptimmune
ADP-0011-007, NCT02992743: Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

Completed
2
23
US
letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine
GlaxoSmithKline
Neoplasms
11/21
03/22
NCT05993299: Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Active, not recruiting
2
7
Europe, Canada, US
Letetresgene autoleucel, Cyclophosphamide, Fludarabine
GlaxoSmithKline
Neoplasms
10/22
07/24
NCT03697824: Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

Withdrawn
1b/2a
0
NA
GSK3377794, Pembrolizumab, Fludarabine, Cyclophosphamide
GlaxoSmithKline, Merck Sharp & Dohme LLC
Neoplasms
07/22
07/22

Download Options